Myriad (A): Breast Cancer Testing in the United States

Kellogg School of Management Cases

ISSN: 2474-6568

Publication date: 20 January 2017


Describes Myriad Genetics and its struggle to develop a genetic testing service while facing challenges from competitors and activist organizations. After Myriad's discovery of the BRCA gene, capable of genetic testing for breast cancer in women, Myriad needed to choose a strategy to provide this service to the public. With several major competitors offering similar services, intense media scrutiny, and a charged activist and political climate, a poor Myriad decision could have major repercussions.



Diermeier, D. and Parthasarathy, S. (2017), "Myriad (A): Breast Cancer Testing in the United States", Kellogg School of Management Cases.

Download as .RIS



Kellogg School of Management

Copyright © 2004, The Kellogg School of Management at Northwestern University

Please note you might not have access to this content

You may be able to access this content by login via Shibboleth, Open Athens or with your Emerald account.
If you would like to contact us about accessing this content, click the button and fill out the form.